February 23, 2021
3 min read
Disclosures: Giugliano reports he received research support from Amgen, Anthos Therapeutics, Daiichi Sankyo; honoraria for CME lectures from Amgen, Daiichi Sankyo, Merck; and consultant fees from Amarin, American College of Cardiology, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers-Squibb, CryoLife, CVS Caremark, Daiichi Sankyo, Eli Lilly, Esperion, Gilead, GlaxoSmithKline, Janssen, Lexicon, Merck, Pfizer, SAJA Pharmaceuticals, Samsung and Servier. Please see the study for all other authors’ relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
ADDED TO EMAIL ALERTS
We were unable to process your request. Please try again later. If you continue to have this issue please contact firstname.lastname@example.org.
Back to Healio
Among women with atrial fibrillation at elevated CV risk, treatment with high-dose edoxaban vs. warfarin conferred greater reduction in hemorrhagic stroke and major bleeding compared with men, with similar efficacy, researchers reported…